The Lancet new text consolidates the status of aspirin drug two years can reduce the risk of colorectal cancer.

In 1988, researchers at the University of Melbourne revealed the protective effectof aspirin on colorectal cancer patients, and more and more researchers began exploring the cancer prevention properties of aspirinA recent study published in the international journal The Lancet adds evidence to the anti-cancer potential of aspirinTaking 600mg of aspirin a day for two years significantly reduces the risk of colorectal cancer in people with Lynch syndrome, and the protective effect lasts for at least 20 years, according to a study led by researchers at the University of Newcastle in the UKLynch syndrome, also known as hereditary non-polypscolor colorectal cancer (HNPCC), is a dominant genetic disease caused mainly by mismatched genetic mutations, and the age of onset of patients is often from under 50 years of ageWhat's scary about it is that not only does it make patients more susceptible to colorectal cancer, endometrial cancer and other diseases, but cancer tends to progress faster, such as the development of adenoma in the colorectal to adenocarcinoma in the general population for 8 to 10 years, while people with Lynch syndrome only need 2 to 3 years or so, the probability of re-onset after surgery is very highTo help people with Lynch syndrome prevent disease, the 1999 Cancer Prevention Program (CaPP) was launched, with the main result being to observe the number, size and histological phases of colorectal cancer detected at least 2 years after the aspirin intervention, and the secondary clinical outcome sized and counted in adenomas and other cancers associated with Lynch syndromeBetween January 1999 and March 2005, a total of 861 people with Lynch syndrome participated in the study, of whom 427 received oral 600 mg of intestinally soluble aspirin daily, 434 received 30g Novelose placebo therapy, each group undertook approximately 25 months of drug intervention and followed up on that basis for more than seven yearsfollow-up results showed that about 5 years after the onset of aspirin treatment, the incidence of colorectal cancer began to vary and the low incidence of cancer was maintained throughout the observation periodOverall, 40 people (9%) in the aspirin group developed the disease in terms of the prevalence of colorectal cancer, compared with 58 (13%) in the placebo groupWhen all cancer types were taken into account, the data were 74 (17%) and 89 (21%) for the aspirin and placebo groups, respectivelyIntentional treatment analysis showed a 35 percent lower risk ratio (HR) in the aspirin and placebo groups and 44 percent lower in patients who took the drug for at least 2 yearsThe protective effects of aspirin have continued for 20 yearsin all, this study showed that taking 600 mg of aspirin a day reduced the risk of colorectal cancer in people at high riskAt the same time, the report notes that the effective dose of aspirin is still uncertain, and researchers will explore this in a follow-up studyReferences: 1.1Cancer with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in CAPP2: a double-blind, randomised, placebo-c.